

Intensity Therapeutics slid Friday after announcing a 1-for-25 reverse split effective Feb. 18 to regain Nasdaq bid-price compliance.
You can purchase shares of Intensity Therapeutics (NASDAQ:INTS) through any online brokerage.
Other companies in Intensity Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Intensity Therapeutics has a consensus price target of $39.25.
The stock price for Intensity Therapeutics (NASDAQ: INTS) is $3.2443 last updated October 20, 2026 at 5:56 PM EDT.
There are no upcoming dividends for Intensity Therapeutics.
Intensity Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Intensity Therapeutics.
Intensity Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct...